Zhejiang Jingxin Pharmaceutical Co Ltd (002020) - Net Assets

Latest as of March 2026: CN¥6.13 Billion CNY ≈ $897.31 Million USD

Based on the latest financial reports, Zhejiang Jingxin Pharmaceutical Co Ltd (002020) has net assets worth CN¥6.13 Billion CNY (≈ $897.31 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥8.06 Billion ≈ $1.18 Billion USD) and total liabilities (CN¥1.93 Billion ≈ $281.83 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 002020 goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric	Value
Current Net Assets	CN¥6.13 Billion
% of Total Assets	76.1%
Annual Growth Rate	23.02%
5-Year Change	21.35%
10-Year Change	141.93%
Growth Volatility	52.09

Zhejiang Jingxin Pharmaceutical Co Ltd - Net Assets Trend (2001–2025)

This chart illustrates how Zhejiang Jingxin Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. See Zhejiang Jingxin Pharmaceutical Co Ltd defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for Zhejiang Jingxin Pharmaceutical Co Ltd (2001–2025)

The table below shows the annual net assets of Zhejiang Jingxin Pharmaceutical Co Ltd from 2001 to 2025. For live valuation and market cap data, see 002020 market cap.

Year	Net Assets	Change
2025-12-31	CN¥5.87 Billion ≈ $859.00 Million	-2.19%
2024-12-31	CN¥6.00 Billion ≈ $878.21 Million	+8.33%
2023-12-31	CN¥5.54 Billion ≈ $810.70 Million	+7.12%
2022-12-31	CN¥5.17 Billion ≈ $756.82 Million	+6.91%
2021-12-31	CN¥4.84 Billion ≈ $707.90 Million	+23.01%
2020-12-31	CN¥3.93 Billion ≈ $575.47 Million	+5.98%
2019-12-31	CN¥3.71 Billion ≈ $542.99 Million	+3.84%
2018-12-31	CN¥3.57 Billion ≈ $522.90 Million	-9.89%
2017-12-31	CN¥3.97 Billion ≈ $580.29 Million	+63.43%
2016-12-31	CN¥2.43 Billion ≈ $355.06 Million	+7.34%
2015-12-31	CN¥2.26 Billion ≈ $330.78 Million	+61.63%
2014-12-31	CN¥1.40 Billion ≈ $204.65 Million	+70.98%
2013-12-31	CN¥817.98 Million ≈ $119.70 Million	+5.88%
2012-12-31	CN¥772.58 Million ≈ $113.05 Million	+0.84%
2011-12-31	CN¥766.17 Million ≈ $112.11 Million	+139.33%
2010-12-31	CN¥320.13 Million ≈ $46.84 Million	+4.22%
2009-12-31	CN¥307.17 Million ≈ $44.95 Million	+1.31%
2008-12-31	CN¥303.19 Million ≈ $44.37 Million	+1.20%
2007-12-31	CN¥299.61 Million ≈ $43.84 Million	+1.70%
2006-12-31	CN¥294.62 Million ≈ $43.11 Million	+1.72%
2005-12-31	CN¥289.64 Million ≈ $42.38 Million	+1.98%
2004-12-31	CN¥284.03 Million ≈ $41.56 Million	+221.15%
2003-12-31	CN¥88.44 Million ≈ $12.94 Million	+40.34%
2002-12-31	CN¥63.02 Million ≈ $9.22 Million	+54.95%
2001-12-31	CN¥40.67 Million ≈ $5.95 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Zhejiang Jingxin Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 141424.7% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Retained Earnings	CN¥3.37 Billion	57.78%
Other Components	CN¥2.46 Billion	42.22%
Total Equity	CN¥5.83 Billion	100.00%

Zhejiang Jingxin Pharmaceutical Co Ltd Competitors by Market Cap

The table below lists competitors of Zhejiang Jingxin Pharmaceutical Co Ltd ranked by their market capitalization.

Company	Market Cap
Dynamic Holding Co. Ltd. TW:3715	$1.58 Billion
Expro Group Holdings NV NYSE:XPRO	$1.58 Billion
Parade Technologies Ltd TWO:4966	$1.58 Billion
Five-Star Business Finance Limited NSE:FIVESTAR	$1.58 Billion
Argan SA PA:ARG	$1.58 Billion
Central Plaza Hotel Public Company Limited BK:CENTEL	$1.58 Billion
LANXESS Aktiengesellschaft F:LXS	$1.58 Billion
Israel Canada TA:ISCN	$1.58 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Zhejiang Jingxin Pharmaceutical Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 5,969,508,653 to 5,833,037,936, a change of -136,470,717 (-2.3%).
Net income of 757,979,439 contributed positively to equity growth.
Dividend payments of 284,853,746 reduced retained earnings.
Other comprehensive income decreased equity by 487,648,812.
Other factors decreased equity by 121,947,599.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	CN¥757.98 Million	+12.99%
Dividends Paid	CN¥284.85 Million	-4.88%
Other Comprehensive Income	CN¥-487.65 Million	-8.36%
Other Changes	CN¥-121.95 Million	-2.09%
Total Change	CN¥-	-2.29%

Book Value vs Market Value Analysis

This analysis compares Zhejiang Jingxin Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 1.85x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has decreased from 279.12x to 1.85x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2001-12-31	CN¥0.04	CN¥12.54	x
2002-12-31	CN¥0.07	CN¥12.54	x
2003-12-31	CN¥0.17	CN¥12.54	x
2004-12-31	CN¥0.58	CN¥12.54	x
2005-12-31	CN¥0.59	CN¥12.54	x
2006-12-31	CN¥0.60	CN¥12.54	x
2007-12-31	CN¥0.62	CN¥12.54	x
2008-12-31	CN¥0.62	CN¥12.54	x
2009-12-31	CN¥0.62	CN¥12.54	x
2010-12-31	CN¥0.65	CN¥12.54	x
2011-12-31	CN¥1.51	CN¥12.54	x
2012-12-31	CN¥1.27	CN¥12.54	x
2013-12-31	CN¥1.35	CN¥12.54	x
2014-12-31	CN¥2.16	CN¥12.54	x
2015-12-31	CN¥3.23	CN¥12.54	x
2016-12-31	CN¥3.11	CN¥12.54	x
2017-12-31	CN¥4.87	CN¥12.54	x
2018-12-31	CN¥4.11	CN¥12.54	x
2019-12-31	CN¥4.54	CN¥12.54	x
2020-12-31	CN¥4.95	CN¥12.54	x
2021-12-31	CN¥5.90	CN¥12.54	x
2022-12-31	CN¥5.98	CN¥12.54	x
2023-12-31	CN¥6.41	CN¥12.54	x
2024-12-31	CN¥6.96	CN¥12.54	x
2025-12-31	CN¥6.77	CN¥12.54	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Zhejiang Jingxin Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 12.99%
The company shows good efficiency in utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 18.63%
• Asset Turnover: 0.50x
• Equity Multiplier: 1.39x
Recent ROE (12.99%) is above the historical average (10.32%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2001	24.52%	4.39%	1.49x	3.75x	CN¥5.91 Million
2002	35.36%	8.25%	1.48x	2.89x	CN¥15.98 Million
2003	28.72%	8.43%	1.16x	2.93x	CN¥16.56 Million
2004	9.23%	7.41%	0.75x	1.66x	CN¥-2.16 Million
2005	6.53%	6.11%	0.53x	2.01x	CN¥-9.81 Million
2006	4.79%	3.24%	0.56x	2.64x	CN¥-15.28 Million
2007	0.50%	0.27%	0.56x	3.41x	CN¥-28.31 Million
2008	-5.92%	-3.47%	0.54x	3.18x	CN¥-47.66 Million
2009	1.24%	0.71%	0.58x	3.03x	CN¥-26.55 Million
2010	4.08%	2.04%	0.66x	3.00x	CN¥-18.70 Million
2011	3.80%	4.10%	0.60x	1.56x	CN¥-47.50 Million
2012	4.10%	3.69%	0.66x	1.68x	CN¥-45.58 Million
2013	7.87%	6.60%	0.74x	1.62x	CN¥-17.45 Million
2014	7.66%	8.67%	0.60x	1.48x	CN¥-32.77 Million
2015	7.49%	11.73%	0.48x	1.33x	CN¥-55.64 Million
2016	8.39%	10.65%	0.57x	1.38x	CN¥-38.35 Million
2017	6.74%	11.91%	0.45x	1.25x	CN¥-127.68 Million
2018	10.37%	12.54%	0.59x	1.40x	CN¥13.10 Million
2019	14.08%	14.27%	0.65x	1.52x	CN¥150.79 Million
2020	16.67%	20.04%	0.57x	1.45x	CN¥261.31 Million
2021	12.72%	17.67%	0.54x	1.33x	CN¥130.80 Million
2022	12.87%	17.52%	0.51x	1.43x	CN¥147.64 Million
2023	11.23%	15.48%	0.50x	1.45x	CN¥67.66 Million
2024	11.93%	17.12%	0.49x	1.42x	CN¥115.01 Million
2025	12.99%	18.63%	0.50x	1.39x	CN¥174.68 Million

Industry Comparison

This section compares Zhejiang Jingxin Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $8,382,925,767
Average return on equity (ROE) among peers: 7.20%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Zhejiang Jingxin Pharmaceutical Co Ltd (002020)	CN¥6.13 Billion	24.52%	0.31x	$1.58 Billion
Shenzhen Neptunus Bioengineering Co Ltd (000078)	$1.78 Billion	1.33%	4.40x	$527.47 Million
Anhui Fengyuan Pharmaceutical Co Ltd (000153)	$775.01 Million	2.45%	0.87x	$355.63 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423)	$9.87 Billion	20.71%	0.25x	$4.12 Billion
Livzon Pharmaceutical Group Inc (000513)	$1.13 Billion	5.48%	0.64x	$2.54 Billion
Wedge Industrial Co Ltd (000534)	$549.14 Million	1.31%	0.01x	$2.15 Billion
Yunnan Baiyao Group Co Ltd (000538)	$39.91 Billion	10.26%	0.35x	$12.31 Billion
Hainan Haiyao Co Ltd (000566)	$445.29 Million	14.73%	0.90x	$871.39 Million
Tus Pharmaceutical Group Co Ltd (000590)	$271.26 Million	1.07%	1.01x	$306.62 Million
Northeast Pharmaceutical Group Co Ltd (000597)	$5.57 Billion	7.36%	1.59x	$910.49 Million
Jilin Aodong Pharmaceutical Group Co Ltd (000623)	$23.53 Billion	7.26%	0.16x	$3.21 Billion

About Zhejiang Jingxin Pharmaceutical Co Ltd

SHE:002020 China Drug Manufacturers - Specialty & Generic

Market Cap

$1.58 Billion

CN¥10.80 Billion CNY

Market Cap Rank

#7105 Global

#1611 in China

Share Price

CN¥12.54

Change (1 day)

+0.88%

52-Week Range

CN¥11.94 - CN¥21.63

All Time High

CN¥25.17